Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Proteus Infections Clear all
Active, not recruiting Phase 2 Interventional

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

NCT04980872
View directory record Official record
Conditions
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
Interventions
Miransertib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Nov 4, 2026, 9:59 AM EST
Completed Phase 1 Interventional

Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome

NCT02594215
View directory record Official record
Conditions
Proteus Syndrome
Interventions
MK-7075 (miransertib)
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
6 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Nov 4, 2026, 9:59 AM EST
Completed No phase listed Observational

Community - Associated Extended-spectrum Beta-lactamases (ESBL)

NCT00363220
View directory record Official record
Conditions
Infection, E Coli Infections, Klebsiella Infections, Proteus Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Nov 4, 2026, 9:59 AM EST
Completed Phase 4 Interventional Results available

Wirelessly Observed Therapy in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis

NCT01960257
View directory record Official record
Conditions
Tuberculosis
Interventions
Digital Health Feedback System, SOC DOT
Device · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Nov 4, 2026, 9:59 AM EST
Active, not recruiting Phase 2 Interventional

MK-7075 (Miransertib) in Proteus Syndrome

NCT04316546
View directory record Official record
Conditions
Proteus Syndrome
Interventions
MK-7075 (miransertib)
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
3 Years to 99 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 4, 2026, 9:59 AM EST
Withdrawn Not applicable Interventional

Proteus Sustained Behavior Change Study

NCT01503008
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Proteus Sustained Behavior Change system, Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)
Device · Drug
Lead sponsor
Proteus Digital Health, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Nov 4, 2026, 9:59 AM EST
Recruiting No phase listed Observational

Protoacoustic Imaging For 3D Mapping

NCT07832617
View directory record Official record
Conditions
Proton Therapy, Radiation Therapy, Secondary Skin Reactions, Liver Cancer, Prostate Cancer
Interventions
Radiacoustic Imaging w/Ultrasound.
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
24 participants
Timeline
2026 – 2030
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 4, 2026, 9:59 AM EST
Completed No phase listed Observational

Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants

NCT01369953
View directory record Official record
Conditions
Coronary Artery Disease, Proteus Syndrome, Coffin - Sins Syndrome, Familial Isolated Hyperparathyroidism, Dubouitz Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Nov 4, 2026, 9:59 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)

NCT03094832
View directory record Official record
Conditions
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
Interventions
Miransertib
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Nov 4, 2026, 9:59 AM EST
Recruiting No phase listed Observational

Study of Proteus Syndrome and Related Congenital Disorders

NCT00001403
View directory record Official record
Conditions
Proteus Syndrome, PIK3CA Related Overgrowth Spectrum
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 99 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 4, 2026, 9:59 AM EST
Recruiting Not applicable Interventional

VenusP-Valve Pivotal Study (PROTEUS STUDY)

NCT06010563
View directory record Official record
Conditions
Pulmonary Regurgitation
Interventions
Transcatheter pulmonary valve implantation (TPVI), VenusP-ValveTM System
Device
Lead sponsor
Venus MedTech (HangZhou) Inc.
Industry
Eligibility
12 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Nov 4, 2026, 9:59 AM EST
Not listed Phase 4 Interventional

Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy

NCT02800655
View directory record Official record
Conditions
HIV
Interventions
Digital Health Feedback System
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Nov 4, 2026, 9:59 AM EST